Abstract:Investigating the predictors for lumbar puncture to diagnose the asymptomatic neurosyphilis among HIV and syphilis co-infected patients in Shanghai, China. Respectively, screening the medical records from August 1, 2009 to June 30, 2015. Those HIV-infected patients with concurrent syphilis who had received lumbar puncture were selected and their clinical and demographic data were recorded. Participants comprised symptomatic and asymptomatic patients. The latter ones could be further divided into 3 groups: late syphilis, early syphilis with anti-syphilis treatment failure, and early syphilis with serum toludine red unheated serum test (TRUST) ≥1:32. Both syphilis stage and anti-syphilis treatment effect were defined by common criteria, and syphilis of unknown duration was considered as late syphilis. Asymptomatic neurosyphilis was defined as neurosyphilis without neurological symptoms such as headache, cognitive dysfunction, motor deficits, auditory or ophthalmic abnormalities, and stroke. Neurosyphilis was defined as reactive cerebrospinal fluid (CSF) TRUST and/or CSF white blood cell >20 cells/μL without other reasons. Mann-Whitney test and Fisher's exact test were used for analyzing the difference between neurosyphilis and non-neurosyphilis group. Logistic regression test was performed to analyze the risk factors for neurosyphilis. In total, 170 participants were collected, and the rate of neurosyphilis was 32.35%. Among all the 105 participants without neurological symptoms, 80 patients were with late syphilis and 25 were with early syphilis. Among the early syphilis patients, 23 had a TRUST ≥1:32 and the other 2 experienced an anti-syphilis treatment failure. The differences of clinical and demographic variables between neurosyphilis and non-neurosyphilis group were not statistically significant except the serum TRUST titer (P < 0.01). From HIV/syphilis co-infected patients with or without neurological symptom, those who had neurological symptoms, CD4 <350 per μL and serological TRUST titer ≥1:16 were 4.9-fold (95% confidence interval [CI]: 2.37-10.31), 4.3-fold (95% CI: 1.17-15.78), and 4.1-fold (95% CI: 1.58-10.76), respectively, more likely to be diagnosed with neurosyphilis. Asymptomatic patients whose serum TRUST titer ≥1:16 were 8.48-fold (95% CI: 1.08-66.63) more likely to have asymptomatic neurosyphilis. Among asymptomatic HIV-infected patients with late syphilis or early syphilis experienced an anti-syphilis treatment failure, those who have a serum TRUST titer ≥1:16 are suggested to perform lumbar puncture in order to avoid delayed diagnosis and the occurrence of severe sequelae of syphilis.

The usefulness of toluidine red unheated serum test in the diagnosis of HIV-negative neurosyphilis.

The optimum condition of the toluidine red unheated serum test for the replacement of the venereal disease research laboratory test in cerebrospinal fluid for neurosyphilis diagnosis

Comparison of the Cerebrospinal Fluid (CSF) Toluidine Red Unheated Serum Test and the CSF Rapid Plasma Reagin Test with the CSF Venereal Disease Research Laboratory Test for Diagnosis of Neurosyphilis among HIV-Negative Syphilis Patients in China

Comparing Noninvasive Predictors of Neurosyphilis among Syphilis Patients with and Without HIV Co-Infection Based on the Real-World Diagnostic Criteria: A Single-Center, Retrospective Cohort Study in China.

The Tradition Algorithm Approach Underestimates the Prevalence of Serodiagnosis of Syphilis in HIV-infected Individuals

Serum TRSUT Titer ≥1

Serum TRSUT Titer ≥1: 16 Is a Predictor for Neurosyphilis Among HIV-Infected Patients With Concurrent Syphilis and No Neurological Symptoms.

Immunohistochemistry detection of Treponema pallidum and its clinical significance

Comparisons of Several Laboratory Tests in the Diagnosis of Neurosyphilis

Clinical Characteristics, Diagnosis, and Predictors of Neurosyphilis Patients with Human Immunodeficiency Virus Co-Infection

Prevalence of and risk factors for neurosyphilis in syphilitic patients with persistently positive nontreponemal serological tests

Selection of Syphilis Serological Detection in Patients with Latent Blood-Transmitted Risk.

Analysis of Treponema Pallidum DNA and CXCL13 in Cerebrospinal Fluid in HIV-Negative Syphilis Patients

Recurrent Syphilis:Clinic Analysis of the Serum in 24 Cases

The Performance of Rapid Plasma Reagin (RPR) Titer in HIV-negative General Paresis after Neurosyphilis Therapy.

Clinical Prediction and Diagnosis of Neurosyphilis in HIV-negative Patients: a Case-Control Study

Diagnostic role of CXCL13 and CSF serology in patients with neurosyphilis

CT and MR findings in HIV-negative neurosyphilis

CXCL13 Chemokine As a Promising Biomarker to Diagnose Neurosyphilis in HIV-negative Patients

A Negative Nontreponemal And/Or Specific Antitreponemal Igm Test Does Not Exclude Active Infectious Syphilis: Evidence from A Rabbit Infectivity Test A Case Report

Evaluation of Cerebrospinal Fluid Ubiquitin C-terminal Hydrolase-L1, Glial Fibrillary Acidic Protein, and Neurofilament Light Protein As Novel Markers for the Diagnosis of Neurosyphilis among HIV-negative Patients.